Side Effects and Safety Side effects Across preclinical studies and the small human trials published to date (~28 subjects across pilot studies), the reported adverse events stay limited: Mild injection-site irritation (rare) No systemic toxicity at therapeutic doses in published reports Oral administration: mild GI upset in sensitive individuals No immunosuppression, hormonal disruption, or metabolic side effects have been observed
Xie Y, Zheng JY, Hou YJ, Li JH, Liu WH, Sun X, et al
The apparent greater frequency of oral nevi in Whites as compared with Asians and Hispanics may be due to the overrepresentation of this group among patients who underwent biopsies
An ideal drug for NASH would be a drug that targets fat deposition, has anti-inflammatory and antifibrotic properties, and reduces cardiovascular risk, which is the most frequent cause of mortality in NASH
If the drugs fail or regulatory hurdles arise, Pfizer will be re-evaluating that $7.3B upfront it handed over
Jadhav and Annapure 2023)
